Equipment and procedure for culturing, separating, and genetically modifying donor cells for reinfusion into a patient

Patent metadata

Field	Value
Publication number	US-11499977-B2
Application number	US-202217725388-A
Country	US
Kind code	B2
Filing date	Apr 20, 2022
Priority date	Dec 7, 2007
Publication date	Nov 15, 2022
Grant date	Nov 15, 2022

Abstract

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

First claim

The invention claimed is:

1. A method for providing a cellular product enriched in target cells,
wherein the method is performed in a single use tubing set that comprises:
(1) a sample processing unit that includes an input port operably connected to a sample chamber, wherein the sample chamber comprises additional ports to supply fresh media and gasses to support culture of cells in the chamber;
(2) a sample separation unit that includes a magnetic separation column, and
(3) fluid circuitry that interconnects the sample processing unit and the sample separation unit so that cells can flow between the sample processing unit and the sample separation unit in either direction;
wherein the method performed in the single use tubing set comprises:
(a) installing the single use tubing set onto an apparatus that is configured to operate the sample processing unit, the sample separation unit, and the fluid circuitry;
(b) receiving a sample of cells through the input port into the sample processing unit;
(c) preparing the sample of cells in the sample processing unit;
(d) transferring the prepared cells from the sample processing unit to the sample separation unit;
(e) separate the prepared cells into target cells and non-target cells in the sample separation unit using the magnetic separation column, allowing non-target cells to pass to a waste container;
(f) transferring the separated target cells back to the sample processing unit;
(g) culturing the target cells with genetic material in the sample chamber, supplying gas and fresh media as needed for the culturing, thereby genetically modifying the cells;
(h) processing the genetically modified cells by washing and adjusting volume; and thereafter
(i) delivering the genetically modified cells as a cellular product to a product collection container;
wherein the single use tubing set constitutes a closed sterile system, whereby the cellular product delivered to the product collection container in step (i) is suitable for administration to a human patient in need thereof.

2. The method of claim 1 , wherein the apparatus operating the single use tubing set includes a holder for the magnetic separation column, a pump, and a plurality of valves that control fluid flow through the fluid circuitry and the separation column.

3. The method of claim 1 wherein the target cells are hematopoietic stem or progenitor cells, dendritic cells, NK-cells, B-cells or monocytes.

4. The method of claim 1 wherein the target cells are T cells.

5. The method of claim 1 , wherein the target cells are positive for one or more markers selected from CD133, CD34, CD3, CD4, 8, 56, 19, 14, CD141 (BDCA-3), CD303 (BDCA-2), CD304 (BDCA-4), CD144, CD10, (BDCA-1), NKp46, NKp80, CD45RO, CD45RA, CD137, CD25, and CD138.

6. The method of claim 1 wherein the preparing in step (c) includes separating the cell sample into white blood cells (WBC) and other cells by density in the sample processing unit.

7. The method of claim 1 , wherein the preparation in step (c) includes culturing the cell sample with one or more cytokines.

8. The method of claim 1 , wherein the separating in step (e) comprises retaining target cells labeled with magnetic particles in the separation column while non-target cells that are not labeled with magnetic particles pass into the waste container.

9. The method of claim 8 , wherein the target cells are labeled with magnetic particles by way of an antibody or other binding partner conjugated to the particle, wherein the antibody or binding partner selectively binds a cell surface antigen on the target cells.

10. The method of claim 1 , wherein the separating in step (e) comprises retaining non-target cells labeled with the magnetic particles in the separation column while target cells that are not labeled with magnetic particles pass into the sample processing unit.

11. The method of claim 10 , wherein the non-target cells are labeled with magnetic particles by way of an antibody or other binding partner conjugated to the particle, wherein the antibody or binding partner selectively binds a cell surface antigen on the non-target cells.

12. The method of claim 1 , wherein the genetic material cultured with the cells in the sample camber in step (g) is a DNA vector.

13. The method of claim 1 , wherein the cells are genetically modified in step (g) to express a T cell receptor.

14. The method of claim 1 , wherein the processing in step (h) comprises removing a volume of the cell culture medium, and resuspending the genetically modified cells in an infusion solution.

15. The method of claim 1 , wherein cells are monitored in the sample processing unit through a window or prism in the sample chamber.

16. The method of claim 2 , wherein the apparatus is operated by a computer that is programmed to direct flow of fluids through the fluid circuitry and the separation column, to control magnetic field strength of the separation column so as to retain and release magnetically labeled target cells, to manage the culturing of the target cells with the genetic material, and thereafter to deliver the cellular product into an output container for administration to the patient.

Assignees

• Miltenyi Biotec Bv & Co Kg

Inventors

• Miltenyi Stefan
• Schimmelpfennig Winfried
• Lantow Holger
• Neuschaefer Niklas Elmar
• Biehl Martin
• Kabaha Eiad
• Schulz Juergen

Classifications

• B03C1/032

  Matrix cleaning systems · CPC title

• B04B2013/006

  Interface detection or monitoring of separated components · CPC title

• A61M2202/0413

  Blood · CPC title

• B03C2201/18

  Magnetic separation whereby the particles are suspended in a liquid · CPC title

• A61M1/3693 Primary

  using separation based on different densities of components, e.g. centrifuging · CPC title